Humacyte (HUMA) Long-Term Deferred Tax (2020)
Humacyte (HUMA) posted quarterly Long-Term Deferred Tax of $20430.0 for Q4 2020.
Humacyte (HUMA) Long-Term Deferred Tax (2020) Analysis & Trends
Humacyte (HUMA) has reported Long-Term Deferred Tax for 1 consecutive years, with $20430.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Long-Term Deferred Tax changed N/A year-over-year to $20430.0; the TTM figure through Dec 2020 stood at $20430.0 (changed N/A YoY), while the FY2020 annual figure was $20430.0, changed N/A from the prior year.
- Long-Term Deferred Tax held at $20430.0 in Q4 2020 per HUMA's latest filing.
- Across five years, Long-Term Deferred Tax topped out at $20430.0 in Q4 2020 and bottomed at $20430.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 20,430.00 |